Navigation Links
How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
Date:6/15/2012

AMSTERDAM, June 15, 2012 /PRNewswire/ --

Dr Alan Ramsay will present findings of a study in patients with Chronic Lymphocytic Leukemia that will contribute to the design of immunotherapeutic strategies leading to the killing of cancer cells at the 17th Congress of the European Hematology Association in Amsterdam.

T cell activation is essential for immunity including the recognition and killing of abnormal target cells such as cancerous cells. T cell activity is tightly regulated by signaling at the contact site (referred to as the "immune synapse") with a target cell. However, the ability of cancer cells to evade T cell recognition and destruction is an emerging hallmark of disease progression. We have previously demonstrated that tumour cells induce impaired T cell immune synapse signaling and killing function in chronic lymphocytic leukaemia patients. The aim of this study was to identify the molecules that mediate this T cell defect in cancer. We designed and performed laboratory assays to identify that the inhibitory molecules CD200, CD270 (HVEM), CD274 (PD-L1), and CD276 (B7-H3) are co-opted by leukaemia cells to induce impaired T cell synapse signalling. We further show that these inhibitory molecules are highly active and mediate impaired T cell function in both haematological malignancies (including follicular lymphoma) and solid carcinoma cells. Of clinical relevance, we demonstrate that the immunomodulatory drug lenalidomide prevented induction of the T cell activation defect by down-regulating tumour cell inhibitory molecule expression and activity. These results establish a novel immune evasion mechanism whereby cancer cells exploit multiple inhibitory signalling pathways to suppress T cell synapse signalling. These pre-clinical findings should help contribute to the design of immunotherapeutic strategies to specifically block these inhibitory molecules in cancer and to repair T cell recognition and killing of cancer
'/>"/>

SOURCE European Hematology Association
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. New method for producing precursor of neurons, bone and other important tissues from stem cells
2. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
3. Notre Dame researchers develop paint-on solar cells
4. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
5. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
6. In solar cells, tweaking the tiniest of parts yields big jump in efficiency
7. Mesenchymal Stem Cells Have New Cell Culture Environment
8. Discovery in Nature elucidates immune cells in skin and supports novel vaccine approach
9. Scientists Discover How a Bacterial Pathogen Breaks Down Barriers to Enter and Infect Cells
10. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
11. Study dusts sugar coating off little-known regulation in cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2015)... ... July 26, 2015 , ... Maine Standards Company, ... / linearity test kit. The VALIDATE® ANEMIA kit contains Ferritin, Folate, and Vitamin ... using the CLSI recommended “equal delta” method for linearity testing and is liquid, ...
(Date:7/24/2015)... Pa. , July 24, 2015 Ryan ... been filed in United States District Court for the Northern ... all persons or entities that purchased the common stock of ... ) between July 31, 2014 and June 15, 2015, inclusive ... than September 8, 2015, move the Court for appointment as ...
(Date:7/24/2015)... July 24, 2015 Equity Research ... BioPharma Inc. (NASDAQ: PDLI ), Arena Pharmaceuticals Inc. ... ), Northwest Biotherapeutics Inc. (NASDAQ: NWBO ), and ... report on PDL BioPharma can be accessed at ... Composite ended at 5,146.41, down 0.49%, the Dow Jones ...
(Date:7/24/2015)... Orexigen Therapeutics, Inc. (Nasdaq: OREX ) ... quarter 2015 on Thursday, August 6 before the market ... update and discuss the financial results in a live ... (5:00 a.m. Pacific Time). The live call ... (domestic) or (847) 413-3238 (international), participant code 40327229. The ...
Breaking Biology Technology:Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5
... ( http://www.amdl.com ),AMDL, Inc. (Amex: ADL ), ... China and the US, today announced that the,Company will ... New,York City on Tuesday, October 7, 2008 at 10:30 ... Hyatt New York Hotel in the Morosco Room., ...
... Proceeds to Support R&D Efforts and Clinical ... BETHESDA, Md., Oct. 3 Micromet, Inc. ... company developing,novel, proprietary antibodies for the treatment ... that it has closed its previously,announced $40 ...
... of Aberdeen and Rothamsted Research for releasing natural insect repellents that ... technology is set to revolutionise how people protect buildings from unwanted ... ... (PRWEB) October 3, 2008 -- Atrium Innovation Ltd has developed a ...
Cached Biology Technology:AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008 2AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008 3Micromet Closes $40 Million Private Equity Placement 2Micromet Closes $40 Million Private Equity Placement 3Micromet Closes $40 Million Private Equity Placement 4New Innovation Set to Revolutionise Spray Technology - Used to Protect Against the Scottish Biting Midge & Help Fight MRSA in the NHS 2New Innovation Set to Revolutionise Spray Technology - Used to Protect Against the Scottish Biting Midge & Help Fight MRSA in the NHS 3New Innovation Set to Revolutionise Spray Technology - Used to Protect Against the Scottish Biting Midge & Help Fight MRSA in the NHS 4
(Date:7/7/2015)... OXFORD, Conn. , July 7, 2015 NXT-ID, Inc. ... company focused on the growing mobile commerce market announces a revised ... airing this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the ...
(Date:6/30/2015)... -- Genisphere announced Tom Bliss ... develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss comes ... of the last 25 years in leadership positions at ... & Johnson. Tom started his career in Investment Banking, ... He graduated from Dartmouth College with a BA in ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2
... the fields of social, biological and medical science will ... discuss how they can cooperate to improve our understanding ... how our genetic inheritance is expressed (epigenetics). This collaboration ... changes have for such key social policy issues as ...
... pharmaceutical companies and four research institutions, working with the ... partnership that aims to speed the discovery of essential ... known as the TB Drug Accelerator (TBDA), will target ... early-stage research. The long-term goal of the TBDA is ...
... is home to a teeming ecosystem of microbes that is ... while the gut microbiota is interacting with our body, they ... study published online in Genome Research , ... set of viruses associated with gut microbiota in global populations. ...
Cached Biology News:World experts meet in Edinburgh to consider how life experiences impact on our genes 27 pharmaceutical companies join academic researchers to speed TB drug discovery 2Gut microbes battle a common set of viruses shared by global populations 2
...
... Clone/PAD: 3B8A10. ... to the C-terminal region ... Specificity: Specific for the ... Reactivity: Human (positive control: ...
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
...
Biology Products: